Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Return on Capital Employed (2016 - 2025)

Karyopharm Therapeutics' Return on Capital Employed history spans 13 years, with the latest figure at 4.01% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 260.0% year-over-year to 4.01%; the TTM value through Dec 2025 reached 4.01%, down 260.0%, while the annual FY2025 figure was 0.93%, 16.0% up from the prior year.
  • Return on Capital Employed reached 4.01% in Q4 2025 per KPTI's latest filing, up from 7.77% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.34% in Q3 2022 to a low of 7.77% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 1.58%, with a median of 0.8% recorded in 2021.
  • Peak YoY movement for Return on Capital Employed: soared 57bps in 2022, then tumbled -687bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.48% in 2021, then crashed by -30bps to 0.62% in 2022, then dropped by -12bps to 0.7% in 2023, then crashed by -102bps to 1.41% in 2024, then tumbled by -184bps to 4.01% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Return on Capital Employed are 4.01% (Q4 2025), 7.77% (Q3 2025), and 6.75% (Q2 2025).